Page 271 - Williams Hematology ( PDFDrive )

246 Part IV: Molecular and Cellular Hematology <CN>: <CT> PB

302. Kramer OH, Zhu P, Ostendorff HP, et al: The histone deacetylase inhibitor valproic acid 308. Elliott PJ, Ross JS: The proteasome: A new target for novel drug therapies. Am J Clin
selectively induces proteasomal degradation of HDAC2. EMBO J 22(13):3411–3420, Pathol 116(5):637–646, 2001.
2003. 309. Pei XY, Dai Y, Grant S: Synergistic induction of oxidative injury and apoptosis in
303. McBride WH, Iwamoto KS, Syljuasen R, et al: The role of the ubiquitin/proteasome human multiple myeloma cells by the proteasome inhibitor bortezomib and histone
system in cellular responses to radiation. Oncogene 22(37):5755–5773, 2003. deacetylase inhibitors. Clin Cancer Res 10(11):3839–3852, 2004.
304. Richardson PG, Mitsiades C, Hideshima T, Anderson KC: Proteasome inhibition in the 310. Wu ZH, Shi Y, Tibbetts RS, Miyamoto S: Molecular linkage between the kinase ATM
treatment of cancer. Cell Cycle 4(2):290–296, 2005. and NF-kappaB signaling in response to genotoxic stimuli. Science 311(5764):1141–
305. Kouroukis TC, Baldassarre FG, Haynes AE, et al: Bortezomib in multiple myeloma: 1146, 2006.
Systematic review and clinical considerations. Curr Oncol 21(4):e573–e603, 2014. 311. Volcic M, Karl S, Baumann B, et al: NF-kappaB regulates DNA double-strand break
306. Bose P, Batalo MS, Holkova B, Grant S: Bortezomib for the treatment of non-Hodgkin’s repair in conjunction with BRCA1-CtIP complexes. Nucleic Acids Res 40(1):181–195,
lymphoma. Expert Opin Pharmacother 15(16):2443–2459, 2014. 2012.
307. Kortuem KM, Stewart AK: Carfilzomib. Blood 121(6):893–897, 2013. 312. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC: Proteasome inhibition as a
novel therapeutic target in human cancer. J Clin Oncol 23(3):630–639, 2005.

Kaushansky_chapter 16_p0213-0246.indd 246 9/18/15 11:58 PM